Hookworm infectious disease

disease
On this page

Also known as BunostomiasesBunostomiasishookworm infectioninfection, hookworminfections, hookworm

Summary

Hookworm infectious disease (MONDO:0005799) is a disease and 33 clinical trials. Top therapeutic interventions include mebendazole, albendazole, and moxidectin. A subtype of infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Clinical trials: 33

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namehookworm infectious disease
Mondo IDMONDO:0005799
EFOEFO:0007314
Is cancer (heuristic)no

Also known as: Bunostomiases · Bunostomiasis · hookworm infection · infection, hookworm · infections, hookworm

Disease family

This is a subtype of infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious diseasehookworm infectious disease

Related subtypes (34): infective endocarditis, hirudiniasis, fungal infectious disease, infectious peritonitis, epididymitis, viral infectious disease, bacterial infectious disease, parasitic infectious disease, abscess, Ciliophora infectious disease, infectious embryofetopathy, mycetoma, infectious disorder of the nervous system, ear infection, sexually transmitted disease, puerperal infection, Acanthamoeba infectious disease, infectious myositis, infective vaginitis, skin disorder caused by infection, respiratory tract infectious disorder, nail infection, infective arthritis, digestive system infectious disorder, nosocomial infection, eye infectious disorder, prosthesis-related infectious disease, vector-borne disease, coinfection, urinary tract infection, hemorrhagic fever, protothecosis, pythiosis, infectious disease with sepsis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Albendazole, Aluminum Hydroxide, Mebendazole.

Clinical trials & evidence

Clinical trials

Clinical trials: 33.

Phase distribution (across all retrieved trials)

PhaseTrials
PHASE111
PHASE27
Not specified7
PHASE34
PHASE43
PHASE2/PHASE31

Top trials by phase / activity

NCTPhaseStatusTitle
NCT07145736PHASE4RECRUITINGMoxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases
NCT03261596PHASE4WITHDRAWNMebendazole Study Against Hookworm Infections in Children and Adolescents in Ghana
NCT03278431PHASE4COMPLETEDTriple Combinations Against Hookworm Infections in Lao
NCT06736691PHASE3ENROLLING_BY_INVITATIONEfficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections
NCT06800248PHASE3NOT_YET_RECRUITINGEfficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections
NCT04700423PHASE2/PHASE3COMPLETEDEfficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration
NCT04726969PHASE3COMPLETEDEfficacy and Safety of MOX/ALB Co-administration
NCT06188715PHASE3COMPLETEDEfficacy and Safety of Moxidectin-Albendazole Co-administration in SAC
NCT03172975PHASE2COMPLETEDEfficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection
NCT03527745PHASE2COMPLETEDAlbendazole Dose Finding and Pharmacokinetics in Children and Adults
NCT03995680PHASE2COMPLETEDEfficacy and Safety of a New Chewable Versus the Swallowable Tablet of Mebendazole Against Hookworm
NCT05017194PHASE2COMPLETEDEfficacy and Safety of Emodepside in Adults Infected With Trichuris Trichiura and Hookworm
NCT05538767PHASE2COMPLETEDEfficacy and Safety of Emodepside in Adolescents and Adults Infected With Hookworm
NCT06184399PHASE2COMPLETEDEfficacy, Safety and Acceptability of Ivermectin ODT in PSAC
NCT06720259PHASE2COMPLETEDEfficacy and Safety of Oxantel Pamoate in Children Infected With Trichuris Trichiura
NCT01940757PHASE1RECRUITINGExperimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
NCT00120081PHASE1COMPLETEDStudy of Na-ASP-2 Human Hookworm Vaccine in Healthy Adults Without Evidence of Hookworm Infection
NCT00473967PHASE1TERMINATEDPhase 1 Trial of Na-ASP-2 Hookworm Vaccine in Previously Infected Brazilian Adults
NCT01261130PHASE1COMPLETEDSafety and Immunogenicity of a Human Hookworm Candidate Vaccine With or Without Additional Adjuvant in Brazilian Adults
NCT01385189PHASE1COMPLETEDSafety and Immunogenicity of a Human Hookworm Candidate Vaccine With Different Doses of a Novel Adjuvant
NCT01717950PHASE1COMPLETEDSafety and Immunogenicity of the Na-APR-1 Hookworm Vaccine in Healthy Adults
NCT02126462PHASE1COMPLETEDSafety and Immunogenicity of Co-Administered Hookworm Vaccine Candidates Na-GST-1 and Na-APR-1 in Gabonese Adults
NCT02143518PHASE1COMPLETEDSafety and Immunogenicity Study of Na-GST-1 With or Without CpG
NCT02476773PHASE1COMPLETEDStudy of Na-APR-1 (M74)/Alhydrogel® Co-administered With Na-GST-1/Alhydrogel in Brazilian Adults
NCT02839161PHASE1COMPLETEDStudy of Co-administered Na-APR-1 (M74) and Na-GST-1 in Gabonese Children
NCT03373214PHASE1COMPLETEDNa-GST-1/Alhydrogel With or Without CpG 10104 in Gabonese Adults
NCT00207753Not specifiedCOMPLETEDEffectiveness of Combined Albendazole and Ivermectin Treatment for Intestinal Worm Infections
NCT00603889Not specifiedCOMPLETEDDevelopment of a Skin Test for the Na-ASP-2 Hookworm Antigen
NCT00939198Not specifiedCOMPLETEDPrevalence of Hookworm Infection and Community Preparedness for Hookworm Vaccine Trials in Endemic Areas of Brazil
NCT01163877Not specifiedCOMPLETEDIron Absorption and Utilization in Adolescents Infected With Malaria Parasites, Hookworms or Schistosoma
NCT02262403Not specifiedUNKNOWNHookworm Immune Regulation Project
NCT04227834Not specifiedUNKNOWNSoil-transmitted Helminth Reinfection Rates After Single and Repeated School Hygiene Education
NCT05914363Not specifiedCOMPLETEDEvaluating Impact of Improved Floors on Health

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
MEBENDAZOLE46
ALBENDAZOLE45
MOXIDECTIN43
PYRANTEL43
HEPATITIS B VIRUS HBSAG SURFACE PROTEIN ANTIGEN42
IVERMECTIN42
OXANTEL24
EMODEPSIDE22
GLA-AF22
CHEMBL478260903
CHEMBL528098503
CHEMBL26329102
CHEMBL408209902
CHEMBL478895102
CHEMBL28380702